Biogen (BIIB.US) stock dropped more than 2% despite stronger-than-expected quarterly figures. During the first quarter, the biotech company earned $5.34 per share, minus some items, on $2.69 billion in sales. Earnings dropped 42% and sales declined 24% compared to previous year. Still both measures came in above market estimates. Analysts expected adjusted profit of $4.97 per share and $2.65 billion in sales. For fiscal 2021, the company raised its adjusted earnings guidance to a range of $17.50 to $19.00 per share from the range of $17.00 to $18.50 per share, but maintained its revenues outlook between $10.45 billion and $10.75 billion. Stifel analysts pointed to the fact that the strong earnings were overshadowed by the uncertainty surrounding the company's Alzheimer’s drug aducanumab.
Biogen (BIIB.US) stock launched today's session with a bearish price gap, however sellers failed to break below the long term upward trendline and price managed to erase some of the losses. If buyers will manage to uphold momentum then another upward impulse towards the major resistance zone around $270 could be launched. However if sellers will manage to regain control then and break below the aforementioned upward trendline then support at $250.49 could be at risk. Source: xStation5
Start investing today or test a free demo
Open account Try demo Download mobile app Download mobile appThis content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
